
Latest Science News
FDA Approves 43 Novel Drugs in 2025, Including 10 First-in-Class Therapies
The FDA approved 43 novel drugs in 2025, featuring breakthroughs like Breyanzi, the first CAR-T therapy for relapsed MZL on December 4. Modeyso became the first systemic therapy for diffuse midline glioma with H3 K27M mutation, approved in August.
Forzinity is the first therapy for Barth syndrome, improving muscle strength by 45% and heart function by 40%.
Breyanzi CAR-T Therapy Approved for Rare Lymphoma
On December 4, 2025, FDA approved Breyanzi as the first CAR-T for adults with relapsed or refractory marginal zone lymphoma (MZL). This therapy reprograms patient immune cells to attack cancer precisely.
It addresses a rare, slow-growing non-Hodgkin lymphoma difficult to treat after relapses.
New Black Hole Accretion Simulations in Full General Relativity
Scientists created the most detailed model of black hole accretion, accounting for gravity and radiation without approximations using supercomputers. Published in The Astrophysical Journal, it reproduces behaviors of ultraluminous X-ray sources and X-ray binaries.
Led by Lizhong Zhang from Institute for Advanced Study and Flatiron Institute.
Subaru Telescope Discovers Hidden Giant Planet and Brown Dwarf
OASIS survey using Subaru Telescope identified a massive giant planet and rare brown dwarf via precise space data and sharp imaging. HIP 71618 B serves as a test target for NASA's Roman Space Telescope coronagraph.
Combines Hipparcos, Gaia data with SCExAO for direct imaging of hidden worlds.
China's Breakthrough in Invasive Brain-Computer Interfaces
China achieved mind-controlled operations like power wheelchairs and robotic dogs via invasive BCI for paralyzed patients. Enables complex real-world interactions through thought alone.
Marks progress in neurotechnology announced December 19, 2025.
Nanocrine Unveils RT-Chip for Real-Time Tumor Monitoring
Nanocrine's RT-Chip biosensor enables real-time tumor activity observation at cellular level. Developed with U.S. Naval Research Lab, NIH, and Frederick Innovative Tech Center.
Improves cancer diagnosis, drug response mapping beyond traditional assays.
Revvity Launches Signals Xynthetica AI for Molecular Design
Revvity's Signals Xynthetica MaaS enables AI-augmented molecular and materials design. Integrates in-silico generation, prediction, optimization in one platform.
Supports de novo design and experimental validation for confident molecule refinement.